Multimedia - Press Room - Novartis Vaccines

Multimedia

People

Daniel Vasella, M.D.
Chairman and Chief Executive Officer (CEO)

Joerg Reinhardt, Ph.D.
Chief Executive Officer (CEO) of Novartis Vaccines and Diagnostics

Rino Rappuoli, Ph.D.
Global Head of Research, Novartis Vaccines and Diagnostics

Novartis

Download high resolution (tif, 3.3MB)

Novartis Vaccines

Download high resolution (jpg, 75KB)

06 May 2008
First Phase III, head-to-head data show Menveo may offer greater protection for adolescents compared to Menactra*. Novartis expects Menveo to be first quadrivalent meningococcal vaccine to protect from early infancy through adulthood. More than 8 million infants and adolescents in the US and a significant number of children and travellers globally could benefit from Menveo[1]

09 January 2008
Data in JAMA show Menveo may provide infants protection against four of the most common meningococcal serogroups - A, C, W-135 and Y. Menveo stimulates broad immune response against meningococcal disease in infants from two months old

We provide medicines to treat and prevent diseases, ease suffering and improve quality of life.